1 hour ago
18
Braveheart Bio Inc., a clinical-stage biopharmaceutical company barely eight months old, has filed for an initial public offering on the Nasdaq. The company is seeking to raise $319 million, backed by a roster of heavyweight life-science investors that includes Andreessen Horowitz’s Bio + Health division.
The filing, submitted to the SEC on July 15, 2026, under the proposed ticker symbol “BRVE,” marks one of the more aggressive IPO timelines in recent biotech history. Founded in November 2025 with a $185 million Series A, Braveheart is now racing toward public markets with clinical data in hand and Phase 3 trials on the horizon.
A crypto VC firm’s non-crypto bet
The other investors lining up behind Braveheart are pure-play life sciences players: Forbion, OrbiMed, and Enavate Sciences. Notably, Braveheart’s IPO filing does not reference any crypto assets or blockchain technologies, emphasizing its commitment to advancing traditional small-molecule therapeutics.
The drug and the data
Braveheart’s lead asset is BHB-1893, an oral cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy, or HCM. In English: it’s a pill that aims to help patients whose heart muscle is abnormally thick, making it harder for the heart to pump blood effectively.
The drug was in-licensed from China’s Hengrui Pharma, a model that’s become increasingly popular in biotech. Rather than spending years and hundreds of millions on early discovery, companies acquire rights to molecules that have already shown promise in overseas trials.
BHB-1893 has posted positive Phase 2 results in both obstructive and non-obstructive forms of HCM. Those results were announced in March and May 2026, respectively. Braveheart plans to initiate a global Phase 3 development program in the coming months, which is likely the primary use case for IPO proceeds.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
English (US) ·